Research and Markets (http://www.researchandmarkets.com/research/6jssrb/rhinovirus) has announced the addition of the "Rhinovirus Infection - Pipeline Review, H2 2013" report to their offering.

'Rhinovirus Infection - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Rhinovirus Infection, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rhinovirus Infection.

Scope

  • A snapshot of the global therapeutic scenario for Rhinovirus Infection.
  • A review of the Rhinovirus Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Rhinovirus Infection pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Companies Involved in Therapeutics Development

  • Boehringer Ingelheim GmbH
  • Theraclone Sciences, Inc.
  • Canopus BioPharma Incorporated
  • Cocrystal Discovery, Inc.
  • Sealife PHARMA GMBH
  • Polyrizon Ltd.

Drug Profiles

  • SLP-0904
  • OBR-5-340
  • CB-1600
  • Drug For Rhinovirus Infection
  • SLP-1001
  • Human Rhinovirus Program
  • PL-402
  • Human Rhinovirus Inhibitors
  • Rhinovirus Program
  • KR-22809
  • Amiloride Derivatives

For more information visit http://www.researchandmarkets.com/research/6jssrb/rhinovirus

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Respiratory